ALTANA: Top line results of first one-year COPD study with Daxas

05-Jul-2005

Following the announcement of the termination of the Daxas® (roflumilast) collaboration with Pfizer, ALTANA disclosed the top line results of the first one-year COPD study of Daxas®. The phosphodiesterase4 (PDE4)-inhibitor Daxas® is an oral investigational, steroid free anti-inflammatory agent being studied for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

In the COPD study "RATIO/M2-112" the primary endpoint of lung function (FEV1) significantly improved with roflumilast treatment compared to placebo.The frequency of moderate and severe exacerbations was a co-primary endpoint. There was no statistically significant reduction in the rate of total exacerbations (7% reduction). The most common adverse events associated with roflumilast treatment were nausea, headache and diarrhea.

After the termination of the Daxas® collaboration with Pfizer ALTANA will continue the development of Daxas®. A marketing authorization application (MAA) for Daxas® is under evaluation by regulatory agencies in Europe.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...